GlassScriptPhysician profile
Jamie Moses
NPI 1356684369
$7,936.93
in general payments reported to CMS, 2019-2025
46 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,086 · 2022: $1,687 · 2023: $1,406 · 2024: $1,223 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,003.00 | 2021-2024 | Mounjaro, Jardiance, Baqsimi |
| Novo Nordisk INC | $887.99 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $823.18 | 2021-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $720.77 | 2021-2024 | |
| Abbvie INC. | $579.72 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.02 | 2021-2024 | Jardiance, Tradjenta |
| Abbott Laboratories | $383.59 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $227.79 | 2022-2025 | |
| Clarus Therapeutics INC. | $216.58 | 2021 | |
| Xeris Pharmaceuticals, INC. | $213.07 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $210.27 | 2021-2024 | Unithroid |
| Insulet Corporation | $180.92 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $157.37 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $143.96 | 2021-2025 | |
| Antares Pharma, INC. | $142.07 | 2022-2024 | Xyosted |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $131.42 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $130.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $95.15 | 2021-2022 | |
| Pfizer INC. | $94.52 | 2022-2024 | |
| Amgen INC. | $92.38 | 2021-2024 | Tepezza, Repatha |
| Cequr Corporation | $88.78 | 2023-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $76.33 | 2021-2022 | |
| Dexcom, INC. | $75.67 | 2024-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $71.61 | 2021-2024 | Strensiq |
| Kyowa Kirin, INC. | $63.81 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $62.91 | 2021-2023 | Tepezza |
| Medtronic, INC. | $59.51 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Venaseal |
| Tandem Diabetes Care, INC. | $58.18 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.91 | 2021-2022 | |
| Esperion Therapeutics, INC. | $55.40 | 2021 | |
| Boston Scientific Corporation | $55.27 | 2023-2025 | General - Erectile Dysfunction |
| Kowa Pharmaceuticals America, INC. | $48.89 | 2021-2023 | Livalo |
| Sequel Med Tech, LLC | $47.71 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $38.87 | 2021-2022 | |
| Ibsa Pharma INC. | $35.99 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.11 | 2021 | |
| Becton, Dickinson and Company | $25.95 | 2021 | |
| Cvrx, INC. | $24.03 | 2025 | Barostim Neo System |
| Alfasigma USA, INC. | $23.42 | 2022 | |
| Bigfoot Biomedical INC | $19.01 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.64 | 2021 | |
| Smith+Nephew, INC. | $17.04 | 2025 | Renasys Touch, Pico 14 |
| Halozyme INC | $15.77 | 2023 | |
| Tactile Systems Technology INC | $15.54 | 2025 | Nimbl, Flexitouch Plus |
| Recordati_rare_diseases_inc. | $15.38 | 2021 | |
| Ascendis Pharma Endocrinology INC | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.